Nuclear Oncology. From Pathophysiology to Clinical Applications

• Constitutes a valuable reference work for nuclear medicine physicians, radiologists, medical and surgical oncologists and others
• Discusses the role of nuclear medicine in the diagnosis, staging, and treatment of patients with specific cancers
• Considers the incidence and clinical aspects of the disease and the use of nuclear imaging
• Describes radionuclide procedures within an integrated framework, thereby identifying the information required for effective treatment of specific tumors
• Supports learning through a series of cases that define and expand the didactic material in the clinical application chapters

This book discusses the role of nuclear medicine in the diagnosis, staging, and treatment of patients with specific cancers. It presents the incidence, pathophysiologic and clinical aspects of the disease, the use of nuclear imaging in diagnosis, staging requirements, management of specific tumors, and surveillance after primary treatment of cancers. It addresses the various diagnostic/therapeutic options that are currently available or are most likely to become available in the near future according to a prioritized approach, thereby keeping to a minimum the number of diagnostic imaging procedures the patient is expected to undergo.

Topics include basic science, clinical applications, radionuclide therapy, radioguided surgery, heart disease in the cancer patient, and adverse effects of cancer therapy. Each clinical chapter discusses the radionuclide procedures within an integrated framework, thereby identifying the information required for effective treatment of specific tumors. The book concludes with a series of cases that define and expand the didactic material in the clinical application chapters. Thoroughly updated and revised, the second edition incorporates advances in imaging and therapy and features the current staging guidelines of the American Joint Committee on Cancer.

With contributions from a group of internationally distinguished practitioners, Nuclear Oncology: From Pathophysiology to Clinical Applications, Second Edition, is a valuable reference for nuclear medicine physicians, radiologists, medical and surgical oncologists, and other clinicians involved in the care and management of cancer patients.

H. William Strauss, MD, currently serves as an Attending Physician on the Nuclear Medicine Service at Memorial Sloan Kettering Cancer Center and Memorial Hospital in New York City. He joined the Memorial Sloan Kettering/Cornell faculty and staff in 2001, following 30 years of faculty, clinical and research appointments in radiology at the medical schools and teaching hospitals of Johns Hopkins, Harvard, Stanford and Cornell University medical centers. Dr. Strauss is one of the pioneers in the field of cardiovascular nuclear medicine and is internationally recognized for his work in that area. He is a past president of the Society of Nuclear Medicine, former editor of the Journal of Nuclear Medicine and sits on the editorial boards of that journal and six other juried publications.

Giuliano Mariani, MD, Professor and Former Chief of Nuclear Medicine and Director of Specialty School of Nuclear Medicine, University of Pisa, Italy. He is the author/co-author of over 300 original articles in peer-reviewed journals and 72 chapters in books and editor/co-editor of 14 books. His professional and scientific interests span all aspects of nuclear medicine, both diagnostic and therapeutic applications, with special emphasis on nuclear oncology.

Duccio Volterrani, MD, is Associate Professor, Department of Translational Research and New Technologies in Medicine, and Director of Nuclear Medicine, University of Pisa, Italy.
Steven M. Larson, MD, is Attending Physician and Head of the Nuclear Medicine Research Laboratory at Memorial Sloan Kettering Cancer Center, New York, NY. His clinical interests focus on the use of positron emission tomography for diagnostic and molecular imaging and he has special expertise in the care and management of patients who receive radiotargeted therapy, particularly for thyroid cancer.